RxDoctor Payments Data

Diana Skirk, MD

Neurology · Melbourne, FLNPI 1841248887

Payments from drug & device makers

$5,107in general payments, 2019–2025

Across 242 payments — averaging $21.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$389
  • Teva Pharmaceuticals USA, Inc.$348
  • Biohaven Pharmaceutical Holding Company Ltd.$347
  • UCB, Inc.$346
  • Eisai Inc.$346
  • Lilly USA, LLC$339
  • plus $3K from 39 others

What the payments were for

  • Speaking & faculty fees$481%
  • Food & beverage$4,94797%
  • Education$1112%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,107 in reported general payments places this provider in the 55th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$214,527
Medicare patients
250
Services billed
11,806

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate14$108,194
Kesimpta PenOfatumumab12$103,146
AptiomEslicarbazepine Acetate18$43,501
BotoxOnabotulinumtoxina26$31,554
UbrelvyUbrogepant24$23,672
RytaryCarbidopa/Levodopa17$22,720
Nurtec OdtRimegepant Sulfate16$19,907
Topiramate ErTopiramate11$15,810
BriviactBrivaracetam16$10,826
Carbidopa-LevodopaCarbidopa/Levodopa85$2,506
Levetiracetam42$2,459
Gabapentin124$1,745
Memantine Hcl57$1,531
Levetiracetam ErLevetiracetam18$1,328
Armodafinil15$1,172

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$308$108,19414 claims
AbbVieBotox, Ubrelvy$316$55,22650 claims
Sunovion Pharmaceuticals Inc.Aptiom$71$43,50118 claims
Amneal Pharmaceuticals LLCRytary$158$22,72017 claims
PfizerNurtec Odt$389$19,90716 claims
UCB, Inc.Briviact$346$10,82616 claims
Upsher-smith Laboratories LLCTopiramate$28$28024 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,434 neurology providers in Florida.

Other neurology in Melbourne

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →